WO2006003220A1 - Procedimiento para la obtención de 2-amino-6-alquil-amino-4,5,6,7-tetrahidrobenzotiazoles - Google Patents
Procedimiento para la obtención de 2-amino-6-alquil-amino-4,5,6,7-tetrahidrobenzotiazoles Download PDFInfo
- Publication number
- WO2006003220A1 WO2006003220A1 PCT/ES2005/000362 ES2005000362W WO2006003220A1 WO 2006003220 A1 WO2006003220 A1 WO 2006003220A1 ES 2005000362 W ES2005000362 W ES 2005000362W WO 2006003220 A1 WO2006003220 A1 WO 2006003220A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- asterisk
- amino
- solvent
- Prior art date
Links
- 0 CC1CC=C(*)CC1 Chemical compound CC1CC=C(*)CC1 0.000 description 2
- HMEKVIBWVMSQQU-UHFFFAOYSA-N CC(CCC1=O)CC1S Chemical compound CC(CCC1=O)CC1S HMEKVIBWVMSQQU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/30—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Definitions
- the invention relates to a process for the preparation of 2-amino-6-n-alkylamino-4,5,6,7-tetrahydrobenzothiazoles, their enantiomers or mixtures thereof, their solvates, hydrates or their pharmaceutically acceptable salts; as well as some of the intermediates of said procedure.
- Pramipexole the generic name of compound (S) -2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, is a commercial product with D-2 agonist activity of dopamine. The product is marketed in the form of dihydrochloride for the treatment of Parkinson's disease and schizophrenia.
- Pramipexole was described for the first time in EP 186 087.
- This patent document describes the production of pramipexole and the like whose key reaction is the halogen shift of an alpha-halo-4-N-alkylamino-cyclohexanone (generally the halogen is bromine) by the sulfur of thiourea and subsequent cyclization on the ketone to give the aminothiazole ring.
- EP 207 696 describes compounds related to pramipexole and the same synthetic approach is used. The drawback of both syntheses is that the preparation of the alpha-halo-4-N-alkylamino-cyclohexanone proceeds in poor performance.
- the invention provides methods for the preparation of 2-amino-6-alkyl-amino-4,5,6,7-tetrahydrobenzothiazoles that overcome the problems of the state-of-the-art synthesis mentioned above.
- the use of bromine is avoided.
- the invention relates to some of the intermediate compounds of the present process.
- the invention provides a process for the preparation of 2-amino-6-alkyl-amino-4,5,6,7-tetrahydrobenzothiazoles of formula (I)
- R and R are, independently of each other, C 1 -C 3 alkyl groups, or R 2 and R 3 together form a C 4 -C 5 divalent radical, or a -CH 2 CH 2 OCH radical 2 CH 2 -, which forms a cycle with the nitrogen atom to which it is attached; optionally in the presence of an acid and a solvent 1, to form an enamine of formula (III)
- 4,5,6,7-tetrahydrobenzothiazoles of formula (I) can be carried out in a conventional manner in three separate stages by purification and / or isolation of the product obtained in each of them, or in a onepot sequence.
- the first step (step a) of the process of the invention consists in the formation of an enamine of formula (III) by reaction of the carbonyl group of the starting compound of formula (II) with a secondary amine, preferably cyclic such as pyrrolidine, morpholine, etc.
- a secondary amine preferably cyclic such as pyrrolidine, morpholine, etc.
- the reaction is optionally carried out in the presence of an acid, for example p-toluenesulfonic acid, and a solvent 1, such as toluene, cyclohexane, diisopropylether, etc., preferably diisopropylether.
- a solvent 1 such as toluene, cyclohexane, diisopropylether, etc., preferably diisopropylether.
- the water that is formed as a byproduct of the reaction is removed from the medium, for example by a Dean-Stark system, by the addition of dehydrating agents such as MgSO 4 , etc.
- the reaction temperature is preferably between 1O 0 C and 9O 0 C, more preferably between 40 0 C and 50 0 C.
- step b) of the process of the invention consists in the introduction of a mercaptan function in the cyclohexene ring.
- the acid and solvent 1 are removed, where appropriate, and the compound of formula (III) is reacted with sulfur in the presence of a solvent 2 to obtain the compound of formula (IV).
- step b) is carried out according to the following protocol: on the residue obtained after the removal of the acid and solvent 1, a solvent 2 is added, for example an alcohol, such as ethanol, methanol, propanol, isopropanol, etc. ., or dimethylformamide, with solvent 2 being preferred methanol.
- step c) of the process of the invention consists in the reaction of the compound of formula (IV) obtained in the previous stage with cyanamide to obtain the compound of formula (I).
- This reaction is conducted preferred mode by adding, to the mixture obtained in the previous step, cyanamide, at a temperature between -10 0 C and 3O 0 C, preferably between O 0 C and 5 ° C.
- the invention is directed to a process for the preparation of 2- amino-6-alkyl-amino-4,5,6,7-tetrahydrobenzothiazoles of formula (I)
- the invention is directed to a process for forming an enamine of formula (III)
- R 1 is a linear or branched C 1 -C 6 alkyl group
- R 2 and R 3 are, independently of each other, C 1 -C 3 alkyl groups, or R and R 3 together form a divalent C 4 -C 5 radical, or a radical - CH 2 CH 2 OCH 2 CH 2 -, which forms a cycle with the nitrogen atom to which it is attached, which consists in reacting a compound of formula (II)
- the synthesis process of the invention not only avoids the use of reagents whose handling can be dangerous, but also has yields greater than 80%. Additionally, the final product is obtained with high purity. In fact, the authors of the invention have observed that the intermediate step of removing acid and solvent 1 prevents the formation of impurities that confer color to the final product of the process of the invention.
- the process of the invention can be carried out in a one pot sequence, which is a great advantage for its industrial scaling.
- the process consists in the dissolution of the compound of formula (II) in a solvent and addition, on the above solution, of sulfur, cyanamide and a secondary amine of formula NHR 2 R 3 , where R 2 and R 3 are those defined above, for example pyrrolidine, at a temperature between -1O 0 C and 5O 0 C, preferably -5 0 C and 2O 0 C.
- the solvent is preferably an alcohol, for example methanol, ethanol or isopropanol.
- the secondary amine can also be dispensed with since the compound of formula (II) has a secondary amino group.
- the separation of the desired (R) or (S) enantiomer is performed.
- conventional methods of optical resolution can be used, for example by fractional crystallization of diastereomeric salts of both enantiomers, for example, using L (+) tartaric acid.
- the compound of formula (I) obtained according to the process of the invention into a pharmaceutically acceptable salt thereof.
- said salts are prepared, for example, by reacting the corresponding basic form of said compound with a stoichiometric amount of the appropriate acid in water, in an organic solvent or in a mixture of both.
- the preferred non-aqueous media are ether, ethyl acetate, ethanol, isopropanol or acetonitrile.
- Acid addition salts include mineral acid addition salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate and phosphate, and organic acid addition salts such as acetate, maleate, fumarate, lactate, citrate, oxalate, succinate, tartrate , malate, mandelate, methanesulfonate and p-toluenesulfonate.
- mineral acid addition salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate and phosphate
- organic acid addition salts such as acetate, maleate, fumarate, lactate, citrate, oxalate, succinate, tartrate , malate, mandelate, methanesulfonate and p-toluenesulfonate.
- the compound of formula (I) can be obtained as a free base or salt. In both cases it is preferably obtained in crystalline form, both as free compounds and solvates (for example, hydrates), both forms being included within the scope of the present invention. Solvation methods are generally known in the state of the art.
- the starting material for the proposed synthesis procedures is a compound of formula (II). This compound can be accessed from a 1,4-cyclohexanedione monoprotegide of general formula (lia):
- R 5 and R 6 form a carbonyl protecting group. While any carbonyl protecting group that is not affected by the reductive animation reaction can be employed, preferably the R 5 and R 6 protecting group is formed by alkyl or benzyl groups or R 5 and R together together form with the two atoms of oxygen a C 2 -C 5 alkanedioxy group.
- the alkyl groups preferably have 1 to 6 carbon atoms, and can be linear or branched.
- Preferred alkyl groups are methyl, ethyl, n-propyl, t-butyl. Some of these products are commercial.
- reaction of this compound of formula (lia) with an alkylamine, such as an amine of formula R 1 NH 2 , where R 1 has the previously mentioned meaning, preferably n-propylamine, in the presence of a reducing agent constitutes a reductive amination, and gives rise to the compound of formula (Ilb).
- a reducing agent such as NaBCNH. 3 o NaB (OAc) 3 H, more preferably NaB (OAc) 3 H.
- the solvents may be ethers, for example tetrahydrofuran (THF), halogenated hydrocarbons, for example dichloromethane, acetonitrile, or others.
- the preferred solvent is tetrahydrofuran, in this case the preferred temperature being between -1O 0 C and 4O 0 C, more preferably between O 0 C and 5 0 C.
- the solvents may be alcohols such as methanol, ethanol, etc., acetonitrile, dimethylformamide, tetrahydrofuran or carboxylic acids, although the preferred solvent is methanol.
- the reductive amination takes place in any of the cases with yields greater than 95%.
- R 5 R and R have the previously mentioned meanings, obtained by this procedure can be used in the next step without being purified, or it can be purified by the formation of a salt, reacting it with an organic acid such as oxalic acid, or inorganic acid, such as hydrochloric acid, etc., in an appropriate solvent, for example an alcohol such as isopropanol, or an ether such as tetrahydrofuran.
- an organic acid such as oxalic acid, or inorganic acid, such as hydrochloric acid, etc.
- an appropriate solvent for example an alcohol such as isopropanol, or an ether such as tetrahydrofuran.
- the compound of formula (II), starting material of step a) of the process of the invention is prepared by removal of the carbonyl protecting group in the compound (Ilb).
- the removal of the carbonyl protecting group is preferably carried out in an acid medium in the presence of water, where the acid can be organic, such as p-toluenesulfonic acid or pyridinium p-toluenesulfonate, or it can be inorganic, for example hydrochloric acid or perchloric acid, etc., preferably hydrochloric acid.
- the reaction can be carried out in the presence of a water-miscible organic solvent, such as an alcohol, for example methanol, ethanol, propanol, etc., or tetrahydrofuran, acetonitrile, etc.
- a water-miscible organic solvent such as an alcohol, for example methanol, ethanol, propanol, etc., or tetrahydrofuran, acetonitrile, etc.
- the deprotection reaction is preferably conducted at a temperature between 2O 0 C and 100 0 C, more preferably between 80 0 C and 90 0 C.
- the invention relates to some of the intermediate compounds of the present process.
- the invention relates to the compounds of formula (III):
- R 2 and R 3 form a ring with the nitrogen.
- R 2 and R 3 together form a radical -CH 2 CH 2 CH 2 CH 2 -.
- the invention also relates to the compounds of formula (IV)
- reaction is allowed to slowly reach room temperature and the reaction control is performed. If the reaction is complete, 100 mL of 10% NaOH are added, the mixture is stirred. The phases are decanted and the aqueous phase is washed twice with CH 2 Cl 2 (50 mL) The organic phase is washed twice with saturated aqueous NaCl solution (50 mL) and dried with sodium sulfate.
- N-4-oxocyclohexyl-n-propyl-amine 133 g, 0.86 mol
- diisopropylether 1.3 L
- pyrrolidine 300 g, 355 mL, 4.25 mol
- p-toluenesulfonic acid 2 O 3.23 g, 0.017 mol
- the reaction mixture is stirred at 40 0 C for 2 h.
- anhydrous MgSO 4 400 g is added and stirred for another 1O h.
- N, N-4-oxocyclohexyl-n-propyl amine (10 g, 64 mmol) in isopropanol (20 mL) sulfur (2.05 g, 64 mmol), cyanamide (2.69 g, 64 mmol).
- the resulting suspension was stirred for several hours at a temperature between 1O 0 C and 20 0 C.
- ethyl acetate 40 mL
- the mixture is cooled for 2 hours between 0oC and 5 ° C.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007517312A JP2008503550A (ja) | 2004-06-25 | 2005-06-24 | 2‐アミノ‐6‐アルキルアミノ‐4,5,6,7‐テトラヒドロベンゾチアゾール類の製造方法 |
DE602005014365T DE602005014365D1 (de) | 2004-06-25 | 2005-06-24 | Verfahren zur gewinnung von 2-amino-6-alkylamino-4,5,6,7-tetrahydrobenzothiazolen |
EP05763015A EP1783120B1 (en) | 2004-06-25 | 2005-06-24 | Method of obtaining 2-amino-6-alkyl-amino-4,5,6,7-tetrahydrobenzothiazoles |
US11/571,270 US7638542B2 (en) | 2004-06-25 | 2005-06-24 | Method of obtaining 2-amino-6-alkyl-amino-4,5,6,7-tetrahydro-benzothiazoles |
CA002569589A CA2569589A1 (en) | 2004-06-25 | 2005-06-24 | Method of obtaining 2-amino-6-alkyl-amino-4,5,6,7-tetrahydrobenzothiazoles |
AT05763015T ATE430740T1 (de) | 2004-06-25 | 2005-06-24 | Verfahren zur gewinnung von 2-amino-6-alkylamino- 4,5,6,7-tetrahydrobenzothiazolen |
US12/619,651 US7875750B2 (en) | 2004-06-25 | 2009-11-16 | Method of obtaining 2-amino-6-alkyl-amino-4,5,6,7-tetrahydrobenzothiazoles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200401559 | 2004-06-25 | ||
ES200401559A ES2245604B1 (es) | 2004-06-25 | 2004-06-25 | Procedimiento para la obtencion de 2-amino-6-alquil-amino-4,5,6,7-tetrahidrobenzotiazoles. |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/571,270 A-371-Of-International US7638542B2 (en) | 2004-06-25 | 2005-06-24 | Method of obtaining 2-amino-6-alkyl-amino-4,5,6,7-tetrahydro-benzothiazoles |
US12/619,651 Division US7875750B2 (en) | 2004-06-25 | 2009-11-16 | Method of obtaining 2-amino-6-alkyl-amino-4,5,6,7-tetrahydrobenzothiazoles |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006003220A1 true WO2006003220A1 (es) | 2006-01-12 |
Family
ID=35614431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2005/000362 WO2006003220A1 (es) | 2004-06-25 | 2005-06-24 | Procedimiento para la obtención de 2-amino-6-alquil-amino-4,5,6,7-tetrahidrobenzotiazoles |
Country Status (8)
Country | Link |
---|---|
US (2) | US7638542B2 (es) |
EP (1) | EP1783120B1 (es) |
JP (1) | JP2008503550A (es) |
AT (1) | ATE430740T1 (es) |
CA (1) | CA2569589A1 (es) |
DE (1) | DE602005014365D1 (es) |
ES (2) | ES2245604B1 (es) |
WO (1) | WO2006003220A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2245604B1 (es) * | 2004-06-25 | 2006-12-01 | Ragactives, S. L. | Procedimiento para la obtencion de 2-amino-6-alquil-amino-4,5,6,7-tetrahidrobenzotiazoles. |
ES2264378B1 (es) | 2005-05-09 | 2007-11-01 | Ragactives, S.L. | Procedimiento para la resolucion de 2-amino-6propilamino-4,5,6,7-tetrahidrobenzotiazol y compuestos intermedios. |
CN110117263B (zh) * | 2019-06-11 | 2020-12-25 | 湖南中医药大学 | 2-氨基-5-酰基噻唑衍生物及其合成方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3682945A (en) * | 1968-07-05 | 1972-08-08 | Exxon Research Engineering Co | Certain 2-acylamino-4,5,6,7-tetrahydrobenzothiazoles |
US5708187A (en) * | 1996-06-27 | 1998-01-13 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists |
WO2004026850A1 (en) * | 2002-09-17 | 2004-04-01 | Generics [Uk] Limited | Process for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiaoles from cyclohexanes and cyclohexanones as intermediates |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA976170A (en) * | 1970-08-25 | 1975-10-14 | Esso Research And Engineering Company | Amino-thiazole and amino-oxazole derivatives and their use to control pests |
IL59334A (en) * | 1979-03-02 | 1984-01-31 | Velsicol Chemical Corp | Tetrahydrobenzothiazolylimidazolidinones and herbicidal compositions containing them |
CA1140227A (en) | 1979-10-19 | 1983-01-25 | Harry H. Kokken | Method of terminating shielded electrical cable and an assembly comprising an electrical connector terminating such cable |
EP0186087B1 (de) | 1984-12-22 | 1989-08-23 | Dr. Karl Thomae GmbH | Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel |
DE3447075A1 (de) * | 1984-12-22 | 1986-07-03 | Dr. Karl Thomae Gmbh, 7950 Biberach | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel |
ZA864626B (en) | 1985-06-24 | 1988-02-24 | Lilly Co Eli | Dialkylaminotetrahydrobenzothiazoles and oxazoles |
DE69610793T2 (de) | 1995-06-23 | 2001-05-03 | Lilly Co Eli | 6-Subsitituierte-1,2,3,4-tetrahydro-9H-Carbazole und 7-substituierte-1OH-Cyclohepta(7,6-B)-Indole |
FI108653B (fi) | 2000-09-18 | 2002-02-28 | Metso Paper Inc | Menetelmä taipumakompensoidun teräpalkin taipuman ja/tai sijainnin säätämiseksi |
US7365086B2 (en) | 2003-07-25 | 2008-04-29 | Synthon Ip Inc. | Pramipexole acid addition salts |
ES2245604B1 (es) | 2004-06-25 | 2006-12-01 | Ragactives, S. L. | Procedimiento para la obtencion de 2-amino-6-alquil-amino-4,5,6,7-tetrahidrobenzotiazoles. |
ES2264378B1 (es) * | 2005-05-09 | 2007-11-01 | Ragactives, S.L. | Procedimiento para la resolucion de 2-amino-6propilamino-4,5,6,7-tetrahidrobenzotiazol y compuestos intermedios. |
-
2004
- 2004-06-25 ES ES200401559A patent/ES2245604B1/es not_active Expired - Fee Related
-
2005
- 2005-06-24 CA CA002569589A patent/CA2569589A1/en not_active Abandoned
- 2005-06-24 WO PCT/ES2005/000362 patent/WO2006003220A1/es active Application Filing
- 2005-06-24 AT AT05763015T patent/ATE430740T1/de not_active IP Right Cessation
- 2005-06-24 US US11/571,270 patent/US7638542B2/en not_active Expired - Fee Related
- 2005-06-24 EP EP05763015A patent/EP1783120B1/en not_active Not-in-force
- 2005-06-24 ES ES05763015T patent/ES2327656T3/es active Active
- 2005-06-24 DE DE602005014365T patent/DE602005014365D1/de active Active
- 2005-06-24 JP JP2007517312A patent/JP2008503550A/ja active Pending
-
2009
- 2009-11-16 US US12/619,651 patent/US7875750B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3682945A (en) * | 1968-07-05 | 1972-08-08 | Exxon Research Engineering Co | Certain 2-acylamino-4,5,6,7-tetrahydrobenzothiazoles |
US5708187A (en) * | 1996-06-27 | 1998-01-13 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists |
WO2004026850A1 (en) * | 2002-09-17 | 2004-04-01 | Generics [Uk] Limited | Process for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiaoles from cyclohexanes and cyclohexanones as intermediates |
Non-Patent Citations (2)
Title |
---|
GEWALD K. ET AL: "Reaction of enamines with sulfur and cyanamide", JOURNAL FUER PRAKTISCHE CHEMIE, vol. 312, no. 5, 1970, pages 776 - 779, XP003009242 * |
GEWALD K. ET AL: "Sulfur heterocyclics. XXX. Simple synthesis of 2-aminothiazoles", JOURNAL FUER PRAKTISCHE CHEMIE, vol. 23, no. 5-6, 1964, pages 298 - 300, XP003009241 * |
Also Published As
Publication number | Publication date |
---|---|
JP2008503550A (ja) | 2008-02-07 |
US20100063324A1 (en) | 2010-03-11 |
EP1783120A1 (en) | 2007-05-09 |
ES2245604B1 (es) | 2006-12-01 |
ES2245604A1 (es) | 2006-01-01 |
ATE430740T1 (de) | 2009-05-15 |
US7875750B2 (en) | 2011-01-25 |
ES2327656T3 (es) | 2009-11-02 |
DE602005014365D1 (de) | 2009-06-18 |
US7638542B2 (en) | 2009-12-29 |
CA2569589A1 (en) | 2006-01-12 |
EP1783120B1 (en) | 2009-05-06 |
US20070161798A1 (en) | 2007-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6986045B2 (ja) | キナーゼを修飾する1h−ピロロ[2,3−b]ピリジン誘導体の合成 | |
EP1318986B1 (en) | Process for preparation of 2-amino-6-(alkyl) amino-4,5,6,7-tetrahydrobenzothiazoles | |
ES2615487T3 (es) | un método eficaz para la preparación de (S)-3-[(1-dimetilamino)etil]-fenil-N-etil-N-metil-carbamato | |
EP1884514B1 (en) | Method for the resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazol and intermediate compounds | |
CN113748101B (zh) | 用于制备对映异构体纯的去甲肾上腺素的方法 | |
US20050080268A1 (en) | Process of preparing O-carbamoyl compounds in the presence of active amine group | |
JP6966656B2 (ja) | 光学活性を有するピペリジン誘導体の中間体およびその製造方法 | |
WO2003101917A2 (en) | A process for the preparation of phenylcarbamates | |
EP2349976B1 (en) | A process for producing (s)-3-[(1-dimethylamino)ethyl]phenyl-n-ethyl-n-methyl-carbamate via novel intermediates | |
JP2008516002A (ja) | 塩酸アトモキセチンの調製方法 | |
ES2401843T3 (es) | Procedimiento de preparación de alfa-aminoacetales ópticamente activos | |
WO2006003220A1 (es) | Procedimiento para la obtención de 2-amino-6-alquil-amino-4,5,6,7-tetrahidrobenzotiazoles | |
ES2553434T3 (es) | Proceso para la preparación de cinacalcet e intermediarios del mismo | |
ES2391032T3 (es) | Procedimiento para la obtención de carbamatos de fenilo | |
ES2235648B1 (es) | Procedimiento para la obtencion de tolterodina. | |
JPWO2011001976A1 (ja) | スレオ−3−(3,4−ジヒドロキシフェニル)−l−セリンの製造法 | |
US20080287687A1 (en) | Production method of diphenylalanine-Ni (II) complex | |
US20100286437A1 (en) | Prepatation method of rivastigmine, its intermediates and preparation method of the intermediates | |
AU2009275667A1 (en) | Process for the preparation of O-desmethylvenlafaxine | |
US20210061757A1 (en) | Process for the synthesis of optically active beta-amino alcohols | |
EP2739610B1 (en) | Process for the manufacture of ivabradine and of intermediates of synthesis thereof | |
EP4063351A1 (en) | Preparation method of quinoline derivative compounds | |
JP2001106661A (ja) | アミン化合物、中間体、製造法および光学分割剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2569589 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007517312 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005763015 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11571270 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007161798 Country of ref document: US Ref document number: 11571270 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005763015 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11571270 Country of ref document: US |